According to GLOBOCAN
2012, there were 14.1 million new cancer cases, 8.2 million cancer deaths
and a staggering 32.6 million people living with cancer (within five years of
diagnosis) worldwide in 2012. The World Health Organization (WHO) has stated
that currently, about one-third of the world’s cancer burden can be decreased
if cancer cases are detected earlier and treatment is provided immediately.
Breast cancer in particular is the second-leading cause of cancer
death in women with nearly 1.7 million new cases diagnosed worldwide in 2012. .
According to the National Cancer Institute (NCI), more than 200,000 women in
the U.S. are diagnosed with breast cancer annually.
Early detection and new treatments have
improved survival rates for breast cancer patients, helping the five-year
survival rate for women diagnosed with cancer to reach nearly 80%. Death rates
from breast cancer have been declining since about 1989; these decreases are
believed to be the result of earlier detection through screening and increased
awareness, as well as improved treatment. Sales of breast cancer diagnostic and drug technologies reached about $22.3 billion globally in 2014 and are expected
to reach $27 billion in 2019, equating to a compound annual growth rate (CAGR)
of 4% (2014–2019).
According to El Camino Hospital’s Radiologist
Dr. Sila Yitta, routine mammograms and self-screening are the best defense,
although many women don't always take advantage. "In my experience it is
hit or miss; some women are consistent in doing breast exams at home, some
women don't do them at all," Yitta said.
New experimental technology could
help thousands of women and doctors screen for breast cancer in a new way,
revolutionizing the screening process. A device called iTBra by Cyrcadia Health
is about to begin its clinical trials in the Bay Area, California, USA. Rather
than a mammogram or ultrasound, this system can be used at home, with
potentially life-saving information transmitted through a smartphone.
The clinical trial being conducted at El Camino Hospital will study the results on women wearing the device for different lengths of time. The goal is to produce accurate readings in roughly two hours, ultimately making the system more convenient for women to use. If the trial is successful, Cyrcadia Health hopes to have the iTBra on the market later this year.
Cancer Vaccines: Technologies and Global Markets (PHM173A)
Cyrcadia Health CEO Rob Royea
says, "It's a wearable device with a number of sensors that check what
happens with your circadian patterns of heat change on your breast over
time." The results are then processed using sophisticated algorithms and
transmitted to a smartphone. "You wear the device for a few hours, and
that information is automatically communicated to your physician," Royea
added.
Because the system is heat based,
developers believe it may also offer advantages for some women with denser
breast tissue, which can be more difficult to image using traditional
mammography.
In addition to R&D efforts in early detection, improved cancer
treatment is making a difference as well, resulting in fewer mastectomies. "The
therapeutic approaches to breast cancer have changed radically since the
1990s," say Stefano Zurrida, MD, and Umberto Veronesi, MD, from the European
Institute of Oncology in Milan, "and the pace of change
shows no signs of slacking."
For related BCC Research market
analysis reports on breast cancer, visit the following links:
Posts
No comments:
Post a Comment